Deep genomic analysis of solid tumours
celldx™ is a tissue based comprehensive molecular profiling of solid tumours with the aim to personalise therapy options. The results are generally available within 8 working days and, in addition to the genetic analysis, also provide information on the benefit of immune checkpoint inhibitors.

About celldx™
To individualise the cancer treatment, celldx™ detects genetic alterations suited for the application of targeted therapies. In addition, immunostaining is performed on the provided tissue samples for PD-L1 suitability in combination with tumour mutational burden and MSI|MMR.
celldx™ provides advantages whenever ...

... there has to be a fast decision about a targeted therapy.

... an immunotherapy is an option for the patient.
celldx™ provides deep molecular analysis for patients with advanced cancers.
SNVs | INDELs
442 Genes
SNV = Single nucleotid variation
INDEL = Insertion / Deletion
CNAs
417 Genes
CNA = Copy number alteration
FUSIONs
51 Genes
TMB
PD-L1
MSI | MMR
MSI = Micro satellite instability
MMR = Mismatch repair
Comprehensive celldx™
-
Indications
Non-Small Cell Lung Cancer (NSCLC)
BiomarkerEGFR Exon 19 deletions
EGFR Exon 21 L858R alterations
T790M
ALK rearrangements
BRAF V600E
ROS1 rearrangements
MET exon 14 skipping mutation/ MET gene amplification
NTRK fusions
PD-L1US FDA-approved TherapyAfatinib, Gefitinib, Osimertinib
Erlotinib, Dacomitinib
Osimertinib
Alectinib, Crizotinib, Ceritinib, Lorlatinib, Brigatinib
Dabrafenib in combination with Trametinib
Entrectinib, Crizotinib, Larlatinib, Ceritinib
Crizotinib
Larotrectinib, Entrectinib
Pembrolizumab, Nivolumab -
Indications
Colorectal Cancer (CRC)
BiomarkerKRAS wild-type (absence of mutations in exons 2, 3 and 4)
KRAS wild-type (absence of mutations in exons 2, 3 and 4) and NRAS wild-type (absence in mutations in exons 2, 3 and 4)
MSI-H/dMMRUS FDA-approved TherapyCetuximab
Panitumumab
Nivolumab ± Ipilimumab or Pembrolizumab -
Indications
Breast Cancer
BiomarkerERBB2 (HER2) amplification
PD-L1
BRCA1/2 alterations
PIK3CAUS FDA-approved TherapyLapatinib, Neratinib, Trastuzumab, Ado-trastuzumab, Emtansine or Pertuzumab
Atezolizumab
Olaparib, Talazoparib
Alpelisib -
Indications
Ovarian Cancer
BiomarkerBRCA1/2 alterations
US FDA-approved TherapyOlaparib, Rucaparib
-
Indications
Melanoma
BiomarkerBRAF V600E
BRAF V600E or V600KUS FDA-approved TherapyDabrafenib or Vemurafenib
Trametinib or Cobimetinib in combination with Vemurafenib -
Indications
Solid Tumours
BiomarkerNTRK
MSI-H/dMMRUS FDA-approved TherapyEntrectinib, Larotrectinib
Pembrolizumab -
Indications
Urothelial Carcinoma
BiomarkerFGFR2, FGFR3 gene alterations
PD-L1US FDA-approved TherapyErdafitinib
Pembrolizumab -
Indications
Prostate Cancer
BiomarkerAR
US FDA-approved Therapy -
Indications
Other cancers
BiomarkerERBB2 (HER2), BRCA1, BRCA2, PIK3CA, NTRK1, NTRK2 and NTRK3
US FDA-approved Therapy
FAQ

The turnaround time, after which the patient or his treating doctor will receive the results, is usually 8 working days from the day the laboratory receives the tissue sample. The test report contains all genomic highlights and lists the particular therapy options.

SNVs, INDELs, CNAs, Fusions, TMB, PD-L1, MSI, MMR, HRD (Homologous recombination deficiency).

Yes, celldx™ can provide information if a target alteration is present. Evaluation of therapies in the need of companion diagnostics across several cancer indications is available as well as clinical trial matching across all solid tumors.

celldx™ provides informed decisions if an immunotherapy is beneficial using genomic signatures like microsatellite instability (MSI), tumor mutational burden (TMB) and PD-L1 status via immunostaining.
Contact

Dr. Stefan Schuster
Managing Director Europe